Rademikibart IV for Acute Asthma and COPD Exacerbation

Part of paid clinical trials in Miami, Florida.

Sponsor
Connect Biopharm LLC
Study ID
NCT07705737
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Asthma Acute
  • COPD Exacerbation Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Rademikibart — DRUG
    Single 300 mg dose as a 2-minute IV push

Study Details

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Key Dates

First listed
Jul 15, 2026
Start date
Jul 30, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rademikibart

Primary Outcome Measure

Change from baseline in post-BD FEV1 [ Time Frame: 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Columbus Clinical Services, LLCMiamiFlorida33135
Radha Adivikolanu
[email protected]
213-522-7990

Find similar trials in Miami, FL

By research site
Columbus Clinical Services, LLC· Miami, FL

Related Studies